



**American Gene  
Technologies®**  
Where Creativity Cures®

[ABOUT](#)

[NEWS](#)

[TECHNOLOGY](#)

[CONTACT](#)



**JEFF GALVIN**  
**CEO AND FOUNDER**  
**AMERICAN GENE TECHNOLOGIES®**

**SHORT BIO**

[LINKEDIN](#) | [TWITTER](#)

Jeff Galvin is the CEO and Founder of American Gene Technologies®, and is passionate about curing the world's worst diseases with gene therapy. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an angel investor in real estate and high tech. He came out of retirement to found and fund AGT™ after meeting Dr. Roscoe Brady at the National Institutes of Health (NIH).

**LONG BIO**

Jeff Galvin is the CEO and Founder of American Gene Technologies® (AGT™). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience. Past companies he has founded were taken public or sold to public companies, such as Varian, which is the leading maker of linear accelerators used in cancer therapy. Driven by his passion to solve complex problems and make a difference in people's lives, Galvin pursued gene therapy research and development to help cure the world's worst diseases.

Transitioning into scientific research, Galvin applied his expertise in critical problem solving to co-create a collaborative lentiviral vector platform for gene therapeutic development with Dr. Roscoe Brady. Dr. Brady was a research scientist at the National Institutes of Health's (NIH) National Institute of Neurological Disorders and Stroke (NINDS) who co-discovered enzymatic defects in lysosomal storage disorders and later developed an enzyme replacement therapy to treat Gaucher disease.

American Gene™ aims to create functional gene therapy cures to treat a broad range of genetic diseases, such as HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer). FDA cleared American Gene Technologies to begin a Phase 1 clinical trial of its HIV cure program in 2020.

In 2022, Galvin appointed Jeff Boyle, PhD, as the company's Chief Science Officer. Dr. Boyle has over 25 years of experience in immunology research, assay development and commercialization, and he has held leadership positions at biopharmaceutical and diagnostic companies. Most recently, Dr. Boyle served as President of Ellume USA LLC, building the organization from the ground up, constructing and commissioning an automated manufacturing facility for COVID-19 home tests in partnership with the Department of Defense. He also served as a board member on the Maryland Technology Council and BioHealth Innovation. Together, Galvin and Boyle aim to analyze the immunological data from the clinical trials for AGT103-T, and if successful, scale to later-stage clinical trials.

# ABOUT AMERICAN GENE TECHNOLOGIES®

## COMPANY DESCRIPTION in 120 Words (Preferred Version)

American Gene Technologies® is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people's lives through genetic medicines that rid the body of disease. American Gene Technologies has been granted numerous patents for the technology used to make AGT103-T and for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

## COMPANY DESCRIPTION in 100 Words

American Gene Technologies® is a gene therapy company with a gene-delivery platform for rapid gene therapy development to cure infectious diseases, cancers, and inherited disorders. Its first-in-human Phase 1 study for HIV gene therapy AGT103-T is nearing completion at trial sites in the Washington, D.C., area. AGT™ has received several patents for its immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. It's developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. This treatment was granted an FDA Orphan Drug Designation and it is expected to reach the clinic in 2023.

## SHORT WEB DESCRIPTION in 49 words, 325 characters

American Gene Technologies® is a gene therapy company with a proprietary lentiviral platform capable of broad applications. FDA cleared American Gene™ to begin a Phase 1 clinical trial of its HIV cure program in 2020, and it has developed a patented immuno-oncology approach to attack a variety of cancers.

## SOCIAL MEDIA (Links to Profiles)

American Gene Technologies

- LinkedIn - <https://www.linkedin.com/company/american-gene-technologies-international-inc/>
- Twitter - [@americangene](#)
- Facebook - [@amerigene](#)
- Instagram - [@americangenetechnologies](#)

Jeff Galvin

- LinkedIn - <https://www.linkedin.com/in/jeff-galvin-60258>
- Twitter - [@jeffreygalvin](#)

---

## Contact Us

9713 Key West Ave, Suite 500, Rockville, MD 20850-3996

Phone: (301) 337-2100 - Fax: (301) 337-2101

[info@americangene.com](mailto:info@americangene.com)

[www.americangene.com](http://www.americangene.com)

For more information about AGT, contact:

Barry Wells at [info@americangene.com](mailto:info@americangene.com)